

Review Article

A Review on Atherosclerosis

Dipti Sharad Pawar*

Received on: 15-11-2014
Accepted on: 17-12-2012
Published on: 15-02-2015

Corresponding Author:

***Dipti Sharad Pawar,**
Lecturer, Shree
Ambabai Talim Sanstha's Diploma in
Pharmacy College, Miraj Maharashtra
India.
Phone: +91 9657701615,
0233 2211528



ABSTRACT

Atherosclerosis is the condition in which deposition of cholesterol on inner linings of arteries take place. In atherosclerosis plaque builds up in a series of stages inside arteries resulting into obstruction to blood flow. Atherosclerosis is the most leading cause of death in industrialized countries. Mostly arteries in the brain, heart, arms, legs & pelvis are affected. The disease is responsible for heart attacks, strokes, aortic aneurysms & peripheral vascular disease. This inflammatory disease is precipitated by elevated levels of low density lipoprotein cholesterol in blood. Endothelial dysfunction is the main stimuli for development of disease. Risk factors of atherosclerosis are both unmodifiable & modifiable which are important in assessment and should be monitored beginning in childhood, even in asymptomatic patients. . The plaques can be predicted by invasive & non-invasive imaging techniques. The blockages are treated by coronary artery bypass, heart catheterization. Medicines along with lifestyle improvement are also useful in management of atherosclerosis. Successful treatment minimizes chances of cardiovascular events, morbidity & mortality.

Key-words: Atherosclerosis, cholesterol, LDL, endothelial dysfunction, risk factors, treatment

*Email Id- diptipawar2@gmail.com

Cite this article as:

Dipti Sharad Pawar, A Review on Atherosclerosis, Asian Journal of Pharmaceutical Technology & Innovation, 03 (10); 2015.
www.asianpharmtech.com

INTRODUCTION:

The term Atherosclerosis is derived from the Greek, athero (meaning gruel or porridge) referring to soft lipid rich material in the center of atheromas and sclerosis (scarring) referring to connective tissue in the plaques.¹ Atherosclerotic vascular disease is the cause of heart attacks, stroke, aortic aneurysms, and peripheral vascular disease, which together represent the most frequent causes of death in the industrialized world. Atherosclerosis is a progressive disease of medium and large sized arteries characterized by focal intimal lesions called atheromas or atherosclerotic plaques that protrude into vessel lumen and eventually leading to various complications. Economic developments, habits of diet and diminished physical activity can favour atherogenesis. Such factors have now become globalize, so that we face an epidemic of atherosclerosis that reaches far beyond Western societies. Risk factors include are non-modifiable like age, male gender, genetics & Modifiable like smoking, obesity, physical inactivity, lipid disorder, hypertension, diabetes, stress. Although low-density lipoprotein (LDL) remains the most important risk factor for atherosclerosis, immune and inflammatory mechanisms of atherosclerosis have gained tremendous interest in the past 20 years.²⁻⁶

PATHOGENESIS OF ATHEROSCLEROSIS:

Atherosclerosis progresses in a series of stages, although some lesions at each stage may not progress further or may even regress if inciting events, such as hypercholesterolemia, smoking, or hypertension, are controlled. Atherosclerosis is a chronic, immunoinflammatory, fibro proliferative disease of medium and large sized arteries. The concepts of atherogenesis have evolved from vague ideas of inevitable degeneration to a well defined scenario of molecular and cellular events. It is now known that endothelial cells, leukocytes, and intimal smooth muscle cells play the key roles in the development of this disease. There are three stages in the life history of an atheroma i.e. initiation, progression and complication⁷⁻⁹.

INITIATION:

Recruitment of mononuclear leucocytes to the intima characterizes initiation of the atherosclerotic lesion. Specific adhesion molecules expressed on the surface of vascular endothelial cells, under the effect of atherogenic stimuli, mediate leukocyte adhesion of mainly monocytes and to a lesser extent, T-lymphocytes to the intima. These adhesion molecules are selectins and members of the immunoglobulin super family such as Vascular Cell Adhesion Molecule-1 (VCAM-1), Intercellular Adhesion Molecule-1 (ICAM-1). Once adherent, the leukocytes enter the intima directed by chemo attractant chemokines such as macrophage chemoattractant protein-1 (MCP-1), Tumor Necrosis Factor (TNF). Cytokines (e.g., interleukin-8) also may play a role in monocyte-macrophage trafficking. The monocytes get transformed to macrophages in the intima. With chronic hyperlipidemia, lipoproteins accumulate inside the intima, subsequently oxidized by the action of oxygen free radicals generated by intimal macrophages. Oxidized LDL further stimulates the release of cytokines and chemokines and flares up the ongoing inflammation. Macrophages internalize oxidized LDL through scavenger receptors and are then called foam cells. Accumulation of foam cells is the hallmark of early and asymptomatic atheromatous precursor, the fatty streak.

PROGRESSION:

As the disease progresses, the inflammatory response is accompanied by a fibro proliferative response mediated by intimal smooth muscle cells. Progressing atheroma involves accumulation of smooth muscle cells which elaborate extracellular matrix macromolecules. Smooth muscle cells and the collagen rich matrix they produce, confer stability to plaques, protecting them against the dreaded consequences of plaque rupture and thrombosis. The smooth muscle cell is the principal connective tissue producing cell in the normal and atherosclerotic intima. Synthetic activity of smooth muscle cells is regarded beneficial whereas their loss is detrimental for the plaque stability. Lack of smooth muscle cells at sites of rupture is

attributed to apoptotic cell death^{10, 11}. Progressing atheroma often accumulates calcium. Calcification probably has a stabilizing effect on the plaque. Neovascularisation is frequent in advanced atherosclerosis. It is probably a marker of ongoing disease activity and characterizes high-risk plaques as the new vessels aggravate risk of intraplaque haemorrhage as well as play role in drawing in more inflammatory cells into the plaque. An atheromatous plaque is composed of cellular component in form of macrophages, smooth muscle cells, T cells, extracellular matrix including collagen, elastic fibres and proteoglycans and lipids, intracellular as well as extracellular. Morphologically, there is an outer fibrous cap composed of collagen and smooth muscle cells. Deep to the cap is a more cellular area containing macrophages, T cells and smooth muscle cells. Beneath it is a necrotic core containing lipid, debris of dead cells, foam cells, fibrin and smooth muscle cells¹².

COMPLICATIONS ASSOCIATED WITH PLAQUES:

A stenotic plaque can gradually occlude a vessel, compromise blood flow and cause ischemic injury to myocardium depending on the blood supply by the affected vessel. In the coronary circulation this occurs when there is loss of 70% of area through which blood can flow. This is known as critical stenosis. The clinical condition is known as stable angina. On the other hand, vulnerable plaques are more prone to acute plaque change like rupture/fissuring, erosion/ulceration and haemorrhage into the atheroma or intraplaque rupture. Intraplaque haematoma further increases the intraplaque pressure making it prone to physical disruption. Plaque vulnerability and destabilization is of multifactorial etiology with inflammation, cap matrix and necrotic lipid core remodeling being important pathobiological processes associated with vulnerability and destabilization. Reduced matrix synthesis as well as increased matrix degradation predisposes vulnerable plaques to rupture in response to extrinsic mechanical or hemodynamic stresses. Other contributing factors towards disruption of plaque are vasospasm, low flow, decreased fibrinolytic activity, procoagulant states etc. Modification of endothelial dysfunction and reduction of vulnerability to plaque rupture and thrombosis may lead to plaque stabilization. A ruptured plaque may manifest clinically as unstable angina, myocardial infarction or sudden death. However, if the plaque disruption is minor, local flow is high, and the fibrinolytic system is active, thrombus formation may be minimal and plaque may remain silent for years and may pose life threatening sudden complications if left undetected. A thrombus may propagate and accumulate additional platelets. Older thrombi may become organized and recanalized. Recent thrombi may dissolve by fibrinolysis.

BIOCHEMICAL BASIS OF ATHEROSCLEROSIS:

The thickening of artery walls is associated with deposits of cholesterol which originate from LDL particles that circulate in the blood. Current research suggests that damage to the endothelial cell inner lining of the vessel allows LDL particles and blood platelets to enter the arterial wall. The LDL contains polyunsaturated fatty acids, which can be attacked by free radicals, generated as a part of normal metabolic processes. As a result LDL becomes oxidized and gives rise to products that are toxic to the cells of the artery wall. Macrophages attempt to remove the oxidized LDL but are unable to degrade the cholesterol, which accumulates as droplets thereby giving a foamy appearance. Cholesterol laden foam cells give characteristic appearance to the fatty streaks. The toxic products can kill the foam cells leaving cholesterol deposits, and the accumulated cholesterol, cells and debris constitute an atheroma. Conditions such as hypercholesterolemia, which is associated with defective LDL receptor increases the risk of atherosclerosis. Besides LDL there are other key players having an important role in atherogenesis as well as its prevention. Numerous large-scale epidemiological studies persistently demonstrated an inverse relationship between plasma high-density lipoprotein cholesterol (HDL-C) level and the risk of coronary heart disease (CHD)¹³.

TYPES OF PLAQUE:

On the basis of pathological characteristics, two types of plaques are identified.

i) Vulnerable plaque: It is also known as non stenotic plaque which is prone to rupture, thrombosis and other complications of plaque. It has a large lipid core, thin fibrous cap, clusters of inflammatory cells mainly foam macrophages, fewer smooth muscle cells. Vulnerable plaque also shows outward remodeling of media, which preserves the vessel lumen known as compensatory enlargement or positive remodeling often leading to underestimation of size by X-ray angiography.

ii) Stable plaque or stenotic plaque: It is characterized by a thick fibrous cap, small lipid core, more of collagen synthesizing smooth muscle cells, less inflammation. It shows less compensatory enlargement. It gradually occludes the vessel well visualized by traditional angiographic techniques. Stenotic lesions give rise to blood vessel luminal compromise. These lesions are easily assessed with conventional radiographic methods¹⁴.

FATE OF ATHEROMATOUS PLAQUE:

Inflammatory response also plays a role in the development of complications of atheromatous plaque, i.e., rupture followed by thromboembolic phenomenon which is mainly responsible for acute complications of atherogenesis like stroke and myocardial infarction. The activated macrophages produce proteolytic enzymes which degrade the collagen and weaken the protective fibrous cap. This, coupled with the production of tissue factor by macrophages provides a prothrombotic milieu leading to thrombosis when plaque ruptures¹⁷.

Thus, atherosclerosis can be considered to be a form of chronic inflammation resulting from interaction between modified lipoproteins, monocyte derived macrophages and T-cells that migrate from blood and the normal cellular elements of the arterial wall.

SITE OF DEVELOPMENT:

The lesions of atherosclerosis occur principally in large and medium sized arteries. The nature of the flow, i.e., shear stress or turbulence, appears to be important in determining where the lesions occur. Changes in flow alter the expression of molecules involved in atherogenesis. Rolling and adherence of monocytes and T-cells occur more at these sites and appear to be critical in determining the sites of lesions¹⁸.

RISK FACTORS:

I) RISK FACTORS THAT CANNOT BE CHANGED:

1) Age:

The risk of cardiovascular events increases as we get older. Age remains one of the strongest predictors of disease. Of course, nothing can be done to reduce age. However, careful attention to diet and maintaining fitness may delay the degenerative changes associated with aging.

2) Gender:

Men are more likely than women to develop coronary heart disease, stroke, and other cardiovascular diseases that are manifestations of atherosclerosis. Whether this is because male hormones— androgens— increase risk or because female hormones— estrogens— protect against atherosclerosis is not completely understood. It is likely that both play a role, but that the protective role of estrogens is the predominant factor. This seems to be supported by the fact that heart disease risk for women rises dramatically after menopause, when their bodies stop producing estrogen.

3) Heredity:

There is no question that some people have a significantly greater likelihood of having a heart attack or stroke because they have inherited a tendency from their parents. In some instances, such as familial hypercholesterolemia (very high levels of cholesterol in the blood), the pattern of inheritance is well understood and the specific biochemical defects are well characterized. For most cardiovascular risk factors, however, the specific way in which inheritance plays a role is not at all clear. As in almost all situations in medicine, both heredity and environment play a role and it is often difficult to know where one stops and the other begins. Prior generations did not have the level of medical care we now enjoy, nor the general awareness about health; the details of the illness that one's grandparents or even parents had may not be precise. Prior to the 1960s, many more people smoked and little attention, if any, was paid to diet and fitness. So it is possible that environmental factors, not genes, were responsible for Grandpa's heart attack or stroke. In practical terms, anyone who has a family history of heart disease that occurred at an early age (below 55) should be especially careful to reduce the impact of any risk that can be controlled. Even if one can successfully control known risk factors, there are, unfortunately, a number of inherited characteristics that we have not yet identified and so cannot favorably affect. Individuals with a history of atherosclerotic cardiovascular disease in the family simply have to be more vigilant if they wish to avoid heart attacks and strokes. We should remember, however, that almost every family has some member who died of a heart or blood vessel disease, since about half of all deaths are attributable to these diseases. If these episodes occurred in relatives who were 75 or 80, it may not be a major cause for concern.

II) RISK FACTORS THAT CAN BE CHANGED:

1) High Blood Pressure:

There are several ways to classify hypertension. It is generally agreed that high blood pressure is defined as readings that consistently exceed 140/90 mm Hg, when measured over a period of time with a blood pressure cuff (sphygmomanometer). Experts focused on diastolic blood pressure, the lower of the two numbers, which represents the resting pressure between heartbeats. Anyone with a reading equal to or greater than 90 mm Hg has diastolic hypertension, regardless of the level of the higher number, which represents the systolic, or pumping, pressure. Some individuals, particularly those over 65 or 70 years of age, have what is called isolated systolic Hypertension.

The most recent expert committee defines this as a systolic blood pressure of 160 mm Hg or more, when the diastolic blood pressure is less than 90 mm Hg. Actually, the levels of both systolic and diastolic blood pressures determine an individual's risk. In fact, of the two readings, the systolic blood pressure may be the superior predictor of all the complications we attribute to hypertension.

There is a wealth of studies to show that successfully treating hypertension will substantially reduce the increased risk associated with it. Fortunately, too, we now have many well-tolerated antihypertensive medications that lower blood pressure and can be taken indefinitely. Although most of the treatment data are based on drugs, such measures as weight loss, salt restriction, and exercise may also lower blood pressure and other complications of hypertension.

2) High Blood Cholesterol and Related Lipid Problems:

Elevated levels of serum lipids (cholesterol and triglycerides) are extremely common and are one of the most important of the heart disease risk factors that can be changed. The level of total cholesterol in the blood is a strong predictor of the likelihood that an individual will develop coronary heart disease and, to a much lesser degree, a stroke. Most experts consider levels under 200 mg/dl to be normal and those between 200 and 239 mg/dl to be borderline high. Levels above 240 mg/dl present an increased risk for a heart attack—more than double the risk of levels below 200 mg/dl.

The most important and best studied are high-density lipoproteins (HDL cholesterol, or HDL-C) and low-density lipoproteins (LDL-C). These levels and their relationship to each other may be more important than total cholesterol levels in predicting heart disease risk. LDL levels over 160 mg/dl are definitely associated with increased risk, while values from 130 to 159 mg/dl are borderline. In contrast, HDL cholesterol is the fraction of cholesterol that appears to protect against coronary heart disease. The higher the level of HDL, the lower the risk. Ideally, it should be at least 35 mg/dl. A ratio of LDL to HDL greater than 3.5 or 4:1 is generally agreed to increase risk. While an individual's lipid profile is affected by age (total cholesterol rises with the years), gender (women tend to have higher levels of HDL), and heredity (elevated cholesterol and triglycerides tend to run in families, and certain families have extremely high levels), the picture can be significantly changed by life-style modifications. A diet low in saturated fat and cholesterol will lower serum cholesterol an average of 5 percent, but this diet may be more effective in some people. The general rule of thumb is that risk of coronary heart disease decreases by 2 percent for every 1 percent drop in total serum cholesterol. Reducing alcohol intake in heavy drinkers and (for those who are overweight) body weight can significantly reduce triglyceride levels. Regular exercise will lower triglycerides and increase HDL cholesterol, and stopping smoking will also raise HDL cholesterol. For people with very high total cholesterol and LDL cholesterol levels, diet and exercise alone may not result in a great enough reduction and these life-style measures may need to be combined with cholesterol-lowering drugs.

3) Lipoprotein (a):

Lipoprotein (a) or "Lp (a)" was discovered in 1963 until recently. Lp (a) is a molecule composed of the protein portion of low-density lipoprotein (LDL), which is called apoB100, and another protein called Ape(a). Ape(a) is very similar chemically to plasminogen, a naturally occurring substance that participates in dissolving clots that form in the bloodstream. Lp(a) has the opposite effect, however it interferes with the normal process of clot lysis (dissolving) and thus may increase the likelihood that once a clot forms, a heart attack or stroke will occur. The impact of Lp (a) levels on the risk of coronary heart disease is as strong as that seen with total cholesterol levels or reduced high-density lipoprotein (HDL) levels, and the increase in risk attributable to high Lp (a) levels is independent of other risk factors.

4) Cigarette Smoking:

Cigarette smoking is a major contributor to coronary heart disease, stroke, and peripheral vascular disease—even though smokers tend to be thinner and to have lower blood pressure than nonsmokers. Individuals, who smoke, regardless of their level of other risk factors or family history, are at significant risk of premature coronary disease and death. Smokers, for example, have less of a chance of surviving a heart attack than nonsmokers. Smoking is the number one risk factor for sudden cardiac death and for peripheral vascular disease. Smoking cigarettes that are low in nicotine and tar does not decrease the risk of heart disease, which is increased by the effect of smoke on blood vessel walls. In fact, some people tend to smoke more and inhale deeply when they switch to this type of cigarette, increasing their exposure to the carbon monoxide in the smoke itself. Fortunately, the risk of heart disease begins to decline rapidly as soon as smokers—even heavy, long-time smokers—stop. Ultimately, their level of risk is almost the same as that of people who have never smoked.

5) Obesity:

Any level of overweight appears to increase heart disease risk. Obesity can predispose the development of other risk factors, and the greater the degree of overweight, the greater the likelihood of developing other antecedents of atherosclerosis (such as high blood pressure and diabetes) that will increase the probability that heart disease will develop. Those who are obese (more than 30 percent over their ideal body weight) are the most likely to develop heart disease, even if they have no other risk factors.

There are two basic patterns of obesity one in which excess fat is found primarily in the abdominal area (the "beer belly" or apple shape) and one in which excess fat deposits from around the hips and buttocks (the pear shape). The former type is called male-pattern obesity or android obesity; the latter, female-pattern or gynecoid obesity. Android obesity, which is also found in some women (especially after menopause), is associated with an increased risk of cardiovascular disease, specifically, coronary heart disease and stroke. A general rule of thumb is that a man's waist measurement should not exceed 90 percent of his hip measurement and that a woman's waist measurement should be no more than 80 percent of her hip measurement. Android obesity appears to be most closely related not only to risk but also to other cardiovascular risk factors—namely hypertension, elevated triglycerides, low HDL cholesterol, elevated blood sugar levels, and diabetes mellitus.

6) Diabetes Mellitus And Insulin Resistance:

Individuals with diabetes mellitus, especially those whose diabetes occurs in adult life, have an increased incidence of coronary heart disease and stroke. Those who have slightly elevated blood sugar levels but do not have detectable diabetes also have an increased risk of developing these problems. Many individuals whose diabetes begins after age 40 or 50 (so-called adult-onset or Type II diabetes) often have higher than normal levels of circulating insulin. The primary role of insulin, a hormone produced by the pancreas, is to maintain blood sugar at normal levels and to assist this body fuel in entering each of the body's cells. For some reason, some individuals do not respond as readily to insulin, and more is required to do the job; they have insulin resistance. Elevated levels of insulin can raise blood pressure and assist in the deposition of and reduce the removal of cholesterol from plaques in the arteries. Both these actions increase the likelihood that atherosclerosis and its complications will develop. Weight reduction and exercise can improve the burning up of blood sugar (glucose) and prevent or slow down the onset of diabetes. Individuals who develop diabetes in childhood (so-called juvenile-onset or Type I diabetes) are more likely to develop kidney and eye problems than coronary heart disease or strokes. In this type of diabetes, insulin is absent due to disease in the pancreas.

7) Fibrinogen:

Serum fibrinogen is a component of the blood that plays a central role in the clotting process. The level of fibrinogen is an independent cardiovascular factor. Individuals with higher levels may be more prone to develop clots in their arteries, thereby increasing the risk of a heart attack or stroke. Fibrinogen levels rise with age, and in that sense are not a risk factor that can be modified. However, fibrinogen levels are also adversely affected by cigarette smoking, which can be controlled.

8) Alcohol:

Drinking four or more drinks per day can have deleterious effects. It raises blood pressure and puts the individual at significant risk of liver damage, central nervous system complications, and a number of other serious problems, some of which are cardiovascular.

9) Behavioral Factors:

Coronary-prone behavior, sometimes referred to as "Type A behavior," is felt by some, but not all, experts to be an important risk factor for coronary heart disease. Current definitions of Type A personality include a sense of time pressure and chronic impatience as well as excessive hostility. Contrary to popular belief, working hard or long hours is not necessarily a feature of the Type A or coronary-prone personality. Type A individuals tend to become upset easily, often for little cause, and are always in a hurry. They are constantly trying to do yet one more thing. Though many individuals who have heart attacks fit this personality description, current studies have not conclusively proved that a Type A personality is a true cardiovascular risk factor.

iii) Protective Factors:

1) Left Ventricular Hypertrophy (LVH):

The left ventricle is the chamber of the heart that pumps blood to all parts of the body except the lungs. The majority of persons with an enlarged left ventricle either has hypertension or has already had a heart attack. Successful treatment of hypertension will not only reduce blood pressure but will also reduce the size of the left ventricle and probably lower the risk associated with ventricular enlargement.

2) Cocaine:

Cocaine constricts the coronary arteries, decreasing blood flow to the arteries of the heart, and reduces the amount of oxygen available to the heart while increasing the heart rate and its demand for oxygen. This combination of effects can precipitate a cardiac crisis and sometimes death, even upon the first use of the drug. Cocaine is also a risk factor for congenital heart disease. Babies born to women who took cocaine during pregnancy are at increased risk of atrial-septal and ventricular-septal defects, as well as other congenital anomalies and adverse effects, such as low birth weight, that are directly related to the drug's action on the mother's cardiovascular system.

3) Exercise:

Exercise also seems to have a positive effect on a number of other risk factors. Regular exercise can lower cardiovascular risk and it should be encouraged for everyone within the limits of each individual.

4) Estrogen:

Estrogen (the major female sex hormone) protects against heart attacks and other forms of cardiovascular disease. Estrogen increases HDL cholesterol, which may explain how the hormone reduces the incidence of heart attacks in premenopausal women. It is now clear that once menopause occurs, women are at the same risk for heart attacks as are men. Thus, it is reasonable to advise that postmenopausal women receive estrogen replacement therapy unless it is medically contraindicated. Although it is likely that estrogen replacement therapy reduces the frequency of heart attacks, such therapy may increase the risk of cancer of the uterus. This risk can be reduced or eliminated by combining estrogen with progesterone, another female sex hormone. As an added advantage, postmenopausal estrogen replacement reduces the severity of osteoporosis—the bone thinning that is a leading cause of death and disability in older women.

PROGRAMME FOR CARDIOVASCULAR RISK FACTOR MODIFICATION:

For those who are free of cardiovascular risk factors or clinical vascular disease, certain simple steps can always help, and will do little if any harm:

Eat a heart-healthy diet—one low in saturated fats and cholesterol. Use monosaturated or polyunsaturated fat.

Reduce weight if it is elevated. Even a small amount of weight loss can be helpful if you are overweight.

Moderate your salt intake. Many people are not sensitive to salt and their blood pressure will not rise even if their intake of table salt and other forms of sodium is high. The problem is, we cannot distinguish who is and is not salt sensitive without complex testing. Most of us eat more salt than we need. Many foods are naturally high in sodium and others have salt added in processing. Simple measures such as not adding salt to the food as it is cooked or at the table will reduce sodium intake to a reasonable amount. This degree of salt restriction is absolutely safe and does not rob food of its taste, especially if herbs and spices are used as alternative flavorings.

Start a regular exercise program. Virtually everyone can benefit from regular exercise. To be helpful, the program need not be too strenuous and can be tailored to an individual's preferences, schedule, and physical capabilities. Regular walking may be all that is necessary.

If you smoke, stop. Nothing will be more beneficial.

If you drink alcohol, do so in moderation.

Learn stress-reduction techniques and avoid reacting to stressful situations in ways that will only serve to aggravate the problem.

Have your risk factor status assessed on a regular basis. A clean bill of health on one occasion does not guarantee a lifetime of protection. Blood pressure, if normal, should be checked every two years or so, and cholesterol, if normal, should be checked every five years¹⁹.

ATHEROSCLEROSIS TREATMENT PROGRAM OVERVIEW:

1. The diagnostic and therapeutic focus for patients with coronary artery, other vascular disease, and diabetes should shift to address the underlying atherosclerosis disease process.
2. Patients with coronary artery, other vascular disease, and/or diabetes should be treated with therapies that have been demonstrated in randomized clinical trials to alter the natural history of atherosclerosis, decrease cardiovascular events, and improve survival.
3. Patients should be treated regardless of whether they have undergone or are undergoing a revascularization procedure and regardless of whether they have symptomatic angina, silent ischemia, or atherosclerosis without ischemia.
4. Antiplatelet agents, beta blocker, ACE inhibitor, statin, omega-3 fatty acids, diet, and an aerobic exercise program should be considered initial and fundamental therapy for all patients with clinical manifestations of any atherosclerotic vascular disease (coronary artery disease, peripheral vascular disease, and/or carotid artery disease) and/or diabetes, irrespective of presence or absence of known vascular disease.
5. Patients with documented atherosclerosis or diabetes should not be discharged from the hospital or leave their outpatient encounter without initiation of treatment, unless contraindicated.
6. Therapies such as type I anti-arrhythmic agents that have been shown to potentially increase the risk of an adverse outcome should, in general, be avoided in patients with AVD.
7. Therapies such as nitrates and calcium channel blockers that provide symptomatic benefit but have not been shown to impact mortality or the incidence of coronary events should, in general, be reserved for patients who remain unacceptably symptomatic despite therapy with ASA, statin, ACE inhibitor, beta blocker, and an exercise program²⁰.

CONCLUSION:

Our understanding of atherosclerosis has progressed remarkably over the past few years. All phases of atherosclerosis are regulated by inflammatory mechanisms that provide overlapping networks of pathways involved in the regulation of immune cell functions, activation of endothelium, and alteration of metabolic parameters. Lp(a) lipoprotein, cholesterol ester transfer protein, apolipoprotein A (the principal apoprotein of high density lipoprotein), and other molecules have little effect on atherogenesis. Thus, although hypercholesterolemia is important in approximately 50 percent of patients with cardiovascular disease, other factors need to be taken into consideration. Atherosclerosis is clearly an inflammatory disease and does not result simply from the accumulation of lipids. If we can selectively modify the harmful components of inflammation in the arteries and leave the protective aspects intact, we

may create new avenues for the diagnosis and management of disease in the 50 percent of patients with cardiovascular disease who do not have hypercholesterolemia. In children and adolescents with a family history of premature coronary artery disease, early identification of the risk factors for atherosclerosis is essential to allow the implementation of preventive measures. Therapeutic lifestyle change (TLC) is an effective approach to lipid management that accommodates opportunities for other types of health risk counseling.

REFERENCES:

1. Harsh Mohan. Textbook of pathology. 3rd edition. New Delhi: Jaypee; 1998. p. 299-308.
2. Ira Tabas: Lipids and atherosclerosis Biochemistry of lipids, lipoproteins & membranes (4th edition)
3. Williams, K.J. and Tabas, I. (1995) The response-to-retention hypothesis of early atherogenesis. *Arterioscler. Thromb. Vasc. Biol.* 15, 551-561.
4. Ross R. 1999. Atherosclerosis—an inflammatory disease. *N. Engl. J. Med.* 340:115–26
5. Weber C, Zernecke A, Libby P. 2008. The multifaceted contributions of leukocyte subsets to atherosclerosis: lessons from mouse models. *Nat. Rev. Immunol.* 8:802–15
6. Hansson GK, Libby P. 2006. The immune response in atherosclerosis: a double-edged sword. *Nat. Rev. Immunol.* 6:508–19
7. Glass CK, Witztum JL. Atherosclerosis: the road ahead. *Cell.* 2001; 104:503–516.
8. Libby P. Inflammation in atherosclerosis. *Nature.* 2002; 420:868 –74.
9. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. *N Engl J Med Screen.* 2004; 85:9-23.
10. Libby P. Changing concepts of atherogenesis. *J Intern Med* 2000; 247:349-358.
11. Geng YJ, Libby P. Progression of atheroma: a struggle between death and procreation. *Arterioscler Thromb Vasc Biol.* 2002; 22:1370–80.
12. Kolodgie FD, Petrov A, Virmani R. Targeting of apoptotic macrophages and experimental atheroma with radiolabeled annexin-V: a technique with potential for noninvasive imaging of vulnerable plaque. *Circulation* 2003; 108:3134-9.
13. Teal AR, Siggers BA. *Biochemical Basis of Disease.* London: 13-15.
14. Libby P, Carli MD, Weissleder R. The Vascular Biology of Atherosclerosis and Imaging targets. *J Nucl Med* 2010; 51;33-37.
15. Gung C, Tsai TH, Chua S, Yang C. Intensity of C-reactive Protein: Immunohistochemical Staining of Atherosclerotic
16. Plaque Macrophages and Extracellular Tissue of Patients with Angina Pectoris undergoing Directional Coronary Atherectomy. *Med J.* 2007 jul; 30(4).
17. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. *Circulation* 2002; 105:1135-43.
18. Ross R. Atherosclerosis-An inflammatory disease. *N Engl J Med* 1999; 340:115-2.
19. How To Lower Your Risk Of Heart Disease, Henry R. Black, M.D. Chapter 3 Cardiovascular Risk Factors:28-35
20. CHAMP – 2005 The UCLA Comprehensive Atherosclerosis Treatment Program
Clinical Practice Guideline